Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCRV6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,584.13 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. The delivery order, issued on January 21, 2026, with an ultimate completion date of February 11, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was established in November 2025 with a $499.999 billion ceiling value and completion date of December 31, 2036.
The PPV-G GEN V is part of a broader $30.3 billion Defense Logistics Agency acquisition strategy designed to supply the Department of Defense with comprehensive pharmaceutical products and medical consumables to support military healthcare facilities worldwide. As an authorized prime vendor under this program, DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through numerous prior delivery orders spanning oncology treatments, biologics, vaccines, specialty pharmaceuticals, and routine medications. The company's established performance across diverse and specialized pharmaceutical requirements positions it as a critical supplier within the federal military medical supply chain, with this delivery order for Stelara—a biologic immunosuppressant—representing routine fulfillment of the vendor's contractual obligations to support DoD healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FCRV6?
SPE2DR26FCRV6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26FCRV6 worth?
The government has obligated $16,584 on SPE2DR26FCRV6.
Is contract SPE2DR26FCRV6 an order under another contract?
Yes. SPE2DR26FCRV6 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRV6 competed?
The extent of competition for SPE2DR26FCRV6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award